PharmaCyte Biotech, Inc. Material Event - What Happened

Hey there! Let's break down some important news about PharmaCyte Biotech, Inc. in a way that makes sense, without all the confusing finance talk. Think of this as me explaining it to you over coffee.

---

1. What happened? (The actual event, in plain English)

Okay, so PharmaCyte Biotech just announced some really significant news regarding its stock. Basically, their stock price has been too low for too long, and because of this, they received a warning from Nasdaq, the stock exchange where their shares are traded.

This means PharmaCyte Biotech is not meeting Nasdaq's rule that requires a company's stock to trade at a minimum of $1.00 per share. If they don't fix this, their stock could eventually be removed from the Nasdaq exchange.

---

2. When did it happen?

This news officially came out on December 1, 2025, which is when PharmaCyte Biotech received the official notice from Nasdaq.

---

3. Why did it happen? (The backstory)

You know how companies list their shares on big stock exchanges like Nasdaq so people can easily buy and sell them? Well, to stay listed, companies have to follow certain rules. One of those rules, called the "Bid Price Rule," says that a company's stock price needs to stay above $1.00 per share.

This particular event happened because PharmaCyte Biotech's common stock closed below $1.00 per share for 30 consecutive business days. When that happens, Nasdaq sends a notice to the company.

---

4. Why does this matter? (The "So What?")

This is a really big deal for a few reasons:

• For the company: Being listed on a major exchange like Nasdaq gives a company credibility and makes it easier for them to raise money and for investors to trade their stock. If PharmaCyte gets delisted, it could hurt their reputation and make it harder to operate.
• For investors: Stocks that trade on Nasdaq are generally seen as more stable and easier to buy and sell than those that might trade on less formal markets (like "over-the-counter" or OTC markets) if delisted. This news creates uncertainty and can make investors nervous.
• For the market: News like this can cause a lot of ups and downs in the company's stock price, as investors react to the potential good or bad outcomes.

---

5. Who is affected?

• PharmaCyte's employees: While not directly impacting their day-to-day work, the company's overall stability and ability to raise capital can affect its long-term prospects.
• Investors/Shareholders: Anyone who owns stock in PharmaCyte Biotech will see their investment react to this news, and they face the risk of their shares being delisted, which can make them harder to sell.
• Partners: Any other companies working with PharmaCyte might also be affected by the perceived stability and financial health of the company.

---

6. What happens next? (Looking ahead)

Now, PharmaCyte Biotech has 180 calendar days, until June 1, 2026, to fix this problem. To regain compliance, their stock's closing bid price needs to be $1.00 or higher for at least 10 consecutive business days during this period.

If they don't meet this deadline, they might be eligible for an additional 180-day period if they meet other listing requirements and show a plan to fix the issue, which could include something called a "reverse stock split" (where they combine multiple shares into one to boost the price). If they still can't fix it, Nasdaq could officially delist their stock.

The company says it will actively monitor its stock price and consider all options, including a reverse stock split (which would need approval from its shareholders).

---

7. What should investors/traders know? (Practical takeaways)

If you own PharmaCyte stock, or are thinking about buying it, this news could definitely shake things up.

• Expect volatility: The stock price might jump or drop significantly as people react to the news and as the company tries to regain compliance.
• Delisting risk: The biggest concern is that the stock could be removed from Nasdaq. If that happens, it would likely trade on less formal markets, which can mean less liquidity (harder to buy and sell) and potentially lower prices.
• Reverse stock split: This is a common tactic companies use to boost their stock price to meet listing requirements. While it increases the per-share price, it doesn't change the overall value of your investment (you'd have fewer shares, but each would be worth more).
• Look for clarity: Pay close attention to any announcements from the company about their plans to address this issue and their progress towards regaining compliance.